Drug promotion enforcement so far similar under new FDA chief, with just 4 letters in first half of 2022
Will a trio of new bosses at the FDA lead to an increase in drug advertising enforcement? It’s a good question, but with few letters sent out so far, there’s just not enough information to tell, says one longtime FDA regulatory watchdog.
“I don’t think there is anything to indicate the Administration is leaning one way or another,” Mark Senak, a lawyer at FleishmanHillard who tracks FDA actions on his Eye on FDA blog, said in an email. “It is worth noting that we have a new FDA Commissioner, new head of CDER and a new head of OPDP which opens up the possibility of change, but there has not yet been enough enforcement activity to identify real change.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.